Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency

Researchers at The University of Texas at Austin have teamed up with pharmaceutical company Eli Lilly and Company to uncover how storage conditions affect mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other treatments, and how to make them more effective.

Originally published at Phys.org